Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — MRI Interventions — Investor Presentation (February 2017)
23 slides from Clearpoint Neuro's investor presentation, Feb 28, 2017
Slide 1: Investor Presentation February 2017
Ticker: MRIC Investor Presentation February 2017 Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2017 MRI INTERVENTIONS, INC. | 1
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements often can be identified by words such as “a
Slide 3: MRI Interventions Investment Opportunity
MRI Interventions Investment Opportunity Commercial Business Drug Delivery Upside Investment Timing Focused commercial effort in neurosurgery; FDA/CE cleared products ClearPoint® System enables real-time MRI guidance for multiple procedures in neurosurgery Products are FDA-cleared, CE-marked; 45+ ho
Slide 4: Key Procedures for Our Technology and the challenges we address
Key Procedures for Our Technology and the challenges we address Therapies Patient Populations Key Challenges We Address Deep Brain Stimulation Medtronic St. Jude* Boston Scientific* Laser Ablation Visualase/Medtronic Monteris Drugs/Biologics Voyager UniQure Merrimack Int’l Stem Cell Medicenna Plus o
Slide 5: ClearPoint Neuro Navigation System
ClearPoint® Neuro Navigation System Utilizes an existing diagnostic or intraoperative MRI to enable real time, intra-operative MRI Imaging during Neurosurgery • ClearPoint Software Proprietary software for targeting and trajectory calculation / determination Dicom image based MRI Safe Hardware MRI s
Slide 6: Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed "Blind"
Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed “Blind” Conventional Stereotactic Procedure ClearPoint Neuro Procedure No real time images – images from earlier in the day or week 80% of interviewed neurosurgeons/neurologists believe real time MRI-guidance will or can become th
Slide 7: ClearPoint Procedure Overview: Target Selection & Entry Planning
ClearPoint Procedure Overview Target Selection & Entry Planning VIDEO © 2017 MRI INTERVENTIONS, INC. | 7
Slide 8: ClearPoint Procedure Overview: Trajectory Alignment & Device Insertion
ClearPoint Procedure Overview SmartFrame Trajectory Guide SmartFrame Hand Controller Trajectory Alignment & Device Insertion VIDEO © 2017 MRI INTERVENTIONS, INC. | 8
Slide 9: Clinical Support, Validation
Clinical Support, Validation Notable Neurosurgeon Supporters Dr. Philip Starr ASSFN Past President Dr. Paul Larson UCSF & VA Dr. Robert Gross Emory University Dr. Robert Wharen, Jr. Mayo Clinic - Jacksonville Dr. Krys Bankiewicz Bankiewicz Lab, UCSF Dr. Russ Lonser OSU - NIH Published Peer-Reviewed
Slide 10: Patented Intellectual Property
Patented Intellectual Property Over 100 issued patents around the world 70+ U.S. Patents 45+ OUS Patents 20+ U.S. Patent Applications 30+ OUS Patent Applications Issued patents cover areas such as: MRI-guided surgical systems that include software and devices; the SmartFrame trajectory guide; other
Slide 11: MRIC's Unique Opportunity in Drug Delivery
MRIC’s Unique Opportunity in Drug Delivery Major Challenges in Delivering Drugs to the Brain - Blood brain barrier blocks systemic delivery (pills, shots, IV) of almost all drugs – 98% of small molecules - Direct injection without ClearPoint is blind, so target is frequently missed - Neopharm Trial
Slide 12: ClearPoint Drug Delivery w/ SmartFlow Cannula
ClearPoint Drug Delivery w/ SmartFlow® Cannula VIDEO SmartFrame targeting cannula, visible under MRI SmartFlow Cannula Inserted to target in the brain Highly precise delivery is evident in the putamen Drug infusion is visible under real-time MRI Example of MR-guided infusion of AAV2-AADC in a patien
Slide 13: ClearPoint Drug Delivery w/ SmartFlow Cannula
ClearPoint Drug Delivery w/ SmartFlow Cannula MR visualization of neuro target MR-guided placement of catheter Therapeutic agent delivered under MR-guidance* Growing Set of Peer-reviewed Publications… Specialized, FDA-cleared drug delivery cannula’s / catheters Conclusion: The ClearPoint system allo
Slide 14: ClearPoint Use in Drug Delivery: Seven Programs Underway
ClearPoint Use in Drug Delivery Seven Programs Underway Now Current Drug Delivery Trials Utilizing the ClearPoint System: AAV2-hAADC for Parkinson’s disease Phase 1 Study at UCSF Initial sponsorship by Michael J. Fox Foundation AAV2-GDNF for Parkinson’s disease Phase 1 Study at the NIH MDNA55 for Re
Slide 15: ClearPoint Revenue Model
ClearPoint Revenue Model BUSINESS MODEL RAZOR / RAZORBLADE ClearPoint Hardware/Software: $100,000 - $150,000 ASP ClearPoint Disposables: $7,500 (average) ASP per procedure with potentially strong margins Recurring revenue from the sale of disposables Procedures covered by existing inpatient DRG reim
Slide 16: Growing the ClearPoint Footprint
Growing the ClearPoint Footprint Installed Base of 46 sites in the US Europe: Warsaw, Poland © 2017 MRI INTERVENTIONS, INC. | 16
Slide 17: ClearPoint US Market Opportunity
ClearPoint US Market Opportunity Parkinson’s Epilepsy Brain Tumors Total Prevalence (US) 1,500,000 2,200,000 80,000 (annual diagnosis) Prevalence – Drug Treatment Resistant (DTR) 125,000 264,000 Incidence – DTR 7,500 18,000 Resections: 80,000 Stereotactic Biopsy: 10,000 ClearPoint Enabled Therapy El
Slide 18: ClearPoint Consumable Revenues
ClearPoint Consumable Revenues $1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q4 2014 Ql Q2 Q3 Q4 2015 Ql Q2 Q3 Q4 2016 © 2017 MRI INTERVENTIONS, INC. | 18
Slide 19: Total Revenue, 2014 - 2016
Total Revenue, 2014 - 2016 $1,800,000 $1,600,000 Total Revenue $1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2014 2015 2016 Consumables Capital / Service Other © 2017 MRI INTERVENTIONS, INC. | 19
Slide 20: Cash Flow From Operations
Cash Flow From Operations $0 -$500,000 -$1,000,000 -$1,500,000 -$2,000,000 -$2,500,000 -$3,000,000 Q4 2014 Q1 Q2 Q3 Q4 2015 Q1 Q2 Q3 Q4 2016 © 2017 MRI INTERVENTIONS, INC. | 20
Slide 21: Experienced, Medical Device Leadership Team
Experienced, Medical Device Leadership Team Key Management Executive Title Prior Experience Frank Grillo President, CEO Peter Piferi COO Wendelin Maners VP Marketing Robert Korn VP Sales Hal Hurwitz CFO Board of Directors Kimble Jenkins, Chairman Maria Sainz Dr. Phillip Pizzo Pascal Girin Timothy Ri
Slide 22: Leading a New, Emerging Industry Trend
Leading a New, Emerging Industry Trend © 2017 MRI INTERVENTIONS, INC. | 22
Slide 23: MRI Interventions, Inc.
Ticker: MRIC MRI Interventions, Inc. Irvine, CA 949.900.6833 www.mriinterventions.com Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2017 MRI INTERVENTIONS, INC. | 23
MRI Interventions — Investor Presentation (February 2017) on 6ix